Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

(KRON) — Biotech firm Genentech is laying off nearly 100 employees at its South San Francisco headquarters, according to a WARN notice from the California Employment Development Department (EDD).

To unlock the full therapeutic potential of targeting PI3K and to reach more patients, the key is “treating the right ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from the open-label, single-arm Phase IV ELEVATUM study ...

Genentech, a member of the Roche (RHHBY), announced that it will present more than 40 abstracts across nine blood disorders at the 66th ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its ...

Mississippi Baptist Medical Center teamed up with Genentech to bring awareness of healthy lungs for Lung Cancer Awareness ...

Since its founding in San Francisco in 1976, biotechnology pioneer Genentech has helped revolutionize the way doctors treat some of the world’s most complex health challenges, including the ...

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma #782 oral presentation ...

– The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME treated with Vabysmo who identify as African American, Black, Hispanic ...